Oculis Holding AG (OCS) EBITDA Margin (2023)

Oculis Holding AG's (OCS) quarterly EBITDA Margin came in at 198.57% in Q4 2023.

Oculis Holding AG (OCS) EBITDA Margin (2023) Analysis & Trends

Oculis Holding AG's EBITDA Margin history runs 1 years deep, the most recent figure standing at 198.57% for Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Alnylam Pharmaceuticals	35.71 Bn	32.70 Bn	959.66 Mn	23.02%

Download Data

Date	Value
Dec 31, 2023	198.57%